Healthtech funding in Q3 2024
European Healthtech startup funding raised during Q3 2024.
In Q3 2024, 95 European Healthtech companies closed 95 funding rounds and raised €1.1B in equity funding (excluding debt and grants), down 69.7% versus Q3 2023. Debt rounds added €20M. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.1B
-69.7% vs Q3 2023 · excl. debt & grants · +€20M debt
Funding rounds
95
-9.5% vs Q3 2023
Companies
95
Top country
UK
Rank among sectors
#4
10.4% of sector funding
Debt financing
€20M
1.7% of total
Top-10 round share
66.1%
of disclosed capital
Rounds ≥ €100M
2
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q3 2024 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €425M | 31 |
| Aug | €364M | 25 |
| Sep | €367M | 39 |
Top countries
by € raisedHealthtech — top countries by capital, Q3 2024 — interactive chart.
Data table
| Healthtech — top countries by capital, Q3 2024 | |
|---|---|
| UK | €564M |
| Germany | €258M |
| France | €118M |
| Switzerland | €112M |
| Spain | €29M |
| Belgium | €23M |
| Denmark | €17M |
| Austria | €13M |
Stage mix
by € raisedHealthtech — stage mix, Q3 2024 — interactive chart.
Data table
| Healthtech — stage mix, Q3 2024 | |
|---|---|
| Series C | €358M |
| Other | €357M |
| Series A | €129M |
| Series D+ | €119M |
| Series B | €108M |
| Seed | €46M |
| Debt | €20M |
| Grant | €13M |
| Pre-Seed | €4.9M |
Exits & M&A
6 Acquisition · 1 Merger8 exits.
Top deals
largest disclosed rounds in Q3 2024| Company | Stage | Date | Amount |
|---|---|---|---|
| Flo Health | Series C | Jul 2024 | €185M |
| Caresyntax | Series C | Aug 2024 | €164M |
| Huma | Series D+ | Jul 2024 | €73M |
| Neo Medical | Other | Sep 2024 | €61M |
| Oxford Nanopore Technologies | Other | Aug 2024 | €59M |
| Constructive Bio | Series A | Sep 2024 | €52M |
| TRIcares | Series D+ | Jul 2024 | €46M |
| Healx | Other | Aug 2024 | €44M |
| Doccla | Series B | Sep 2024 | €42M |
| PhoreMost | Series B | Sep 2024 | €39M |
| Abolis Biotechnologies | Other | Sep 2024 | €35M |
| Vandria | Series A | Aug 2024 | €28M |
| Protembis | Debt | Jul 2024 | €20M |
| Brightflow | Series A | Sep 2024 | €17M |
| Vaxdyn | Other | Sep 2024 | €15M |
Top investors
most active in Q3 2024, by deal count- High-Tech Gründerfonds (HTGF)3 deals
- Venture Kick3 deals
- Aescuvest2 deals
- Bayern Kapital2 deals
- Berlin Angel Fund2 deals
- Bertelsmann Investments2 deals
- BGF2 deals
- Carma Fund2 deals
- Elaia2 deals
- European Innovation Council (EIC) Accelerator Programme2 deals